Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Bio-Techne (TECH) Reports Earnings Tomorrow: What To Expect

February 02, 2026 at 22:04 PM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

TECH Cover Image

Life sciences company Bio-Techne (NASDAQ: TECH) will be announcing earnings results this Wednesday before market open. Here’s what to look for.

Bio-Techne missed analysts’ revenue expectations by 1.7% last quarter, reporting revenues of $286.6 million, down 1% year on year. It was a softer quarter for the company, with a miss of analysts’ revenue estimates and a miss of analysts’ organic revenue estimates.

Is Bio-Techne a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Bio-Techne’s revenue to decline 2.3% year on year to $290.2 million, a reversal from the 9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.43 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bio-Techne has missed Wall Street’s revenue estimates four times over the last two years.

Looking at Bio-Techne’s peers in the research tools & consumables segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Thermo Fisher delivered year-on-year revenue growth of 7.2%, beating analysts’ expectations by 2.1%, and Revvity reported revenues up 5.8%, topping estimates by 1.1%. Thermo Fisher traded down 4.8% following the results.

Read our full analysis of Thermo Fisher’s results here and Revvity’s results here.

Investors in the research tools & consumables segment have had steady hands going into earnings, with share prices flat over the last month. Bio-Techne is up 5.6% during the same time and is heading into earnings with an average analyst price target of $70 (compared to the current share price of $65.57).

P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article